Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41806838.
- Also identified by DOI 10.1016/j.xcrm.2026.102657 and PMC identifier 13006404.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adult-onset immunodeficiency (AOID) can be associated with anti-interferon (IFN)-γ autoantibodies (AIGAs). Rituximab (RTX) reduces circulating B cells but often fails to eliminate AIGAs, suggesting the presence of long-lived antibody-secreting cells (ASCs) in immune-privileged sites. Here, we identified 23 distinct IFN-γ-specific monoclonal antibodies (mAbs) from bone marrow (BM) ASCs of AOID patients using microwell array chip technology and single-cell RNA sequencing. Competitive assays demonstrated that neutralizing mAbs disrupt IFN-γ engagement with IFN-γR1 or IFN-γR2, impairing JAK-STAT1 signaling. Structural analysis of neutralizing mAb A01BM-03 revealed its binding to a quaternary epitope on dimeric IFN-γ, disrupting IFN-γR2 interaction. Notably, clonally expanded IFN-γ-specific ASCs were localized within a CD11c<sup>+</sup>ZEB2<sup>+</sup> age-associated B cell (ABC)-like plasma cell cluster in one AOID patient, implicating its role in AOID pathogenesis. These findings provide direct evidence for IFN-γ-specific ASCs in the BM despite RTX treatment, supporting targeted ASC therapy to restore immune homeostasis in AOID.
Medical subject headings
- Interferon-gamma
- Autoantibodies
- Antibodies, Neutralizing
- Plasma Cells
- Immunologic Deficiency Syndromes
- Bone Marrow Cells